MyFinsight
Home
Blog
About
Proceeds from
borrowings, net
$2,400,000K
(38.46%↑ Y/Y)
Depreciation and
amortization
$236,100K
(21.51%↑ Y/Y)
Amortization of acquired
inventory step-up
$202,800K
(286.29%↑ Y/Y)
Acquired in-process
research and development
$100,000K
Payments related to
issuance of stock for...
-$6,000K
(1.64%↑ Y/Y)
Net income
$97,500K
(-84.64%↓ Y/Y)
Share-based compensation
$77,400K
(3.34%↑ Y/Y)
Inventory
-$75,700K
(-184.20%↓ Y/Y)
Other
-$36,000K
(-287.10%↓ Y/Y)
Income tax assets and
liabilities
$13,800K
(102.29%↑ Y/Y)
Excess and
obsolescence charges related...
$5,100K
(-27.14%↓ Y/Y)
Contingent consideration
$2,500K
(-81.06%↓ Y/Y)
Net cash flow
provided by (used in)...
$1,296,000K
(11176.92%↑ Y/Y)
Net cash flow
provided by (used in)...
$448,900K
(178.99%↑ Y/Y)
Canceled cashflow
$1,110,000K
Canceled cashflow
$401,500K
Net increase
(decrease) in cash and cash...
-$2,094,300K
(-2371.48%↓ Y/Y)
Canceled cashflow
$1,744,900K
Proceeds from sales and
maturities of marketable...
$1,515,200K
Repayments of borrowings
$1,096,700K
(-37.33%↓ Y/Y)
Other
-$13,300K
(-1008.33%↓ Y/Y)
Accounts
receivable-Nonrelated Party
$132,300K
(1360.00%↑ Y/Y)
Accounts
receivable-Related Party
$91,600K
(38.37%↑ Y/Y)
Other changes in
operating assets and...
$54,000K
(145.45%↑ Y/Y)
Accrued expense and
other current...
-$49,700K
(-173.08%↓ Y/Y)
(gain) loss on
strategic investments
$42,800K
(455.84%↑ Y/Y)
Deferred income taxes
-$27,600K
(11.82%↑ Y/Y)
Impairment of intangible
assets
-$3,500K
(-200.00%↓ Y/Y)
Net cash flow
provided by (used in)...
-$3,839,200K
(-6635.44%↓ Y/Y)
Canceled cashflow
$1,515,200K
Acquisition of apellis, net
of cash acquired
$5,065,100K
Purchases of marketable
securities
$147,800K
Payments to acquire in
process research and...
$100,000K
Purchases of property,
plant and equipment
$40,900K
(53.76%↑ Y/Y)
Other
$600K
(-98.03%↓ Y/Y)
Back
Back
Cash Flow
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)
source: myfinsight.com